Nina Lin, MD
Assistant Professor
Boston University School of Medicine
Dept of Medicine
Infectious Diseases

MD, Harvard Medical School




Dr. Nina Lin is a physician scientist who is engaged in HIV translational research. Her research is focused on understanding the effect of chronic HIV infection on aging of the immune system and chronic inflammation. She is the PI on several clinical trials, including being a co-Chair of ACTG A5325 and A5220s, to evaluate interventions which may improve or alter the clinical course of chronic HIV infection. Her research while at MGH/BWH had been on understanding HIV-1 coreceptor usage in subtype C infection and the factors associated with its switching. She is the Director of the BU Infectious Disease Clinical Research Unit (CRU) where several HIV and/or infectious diseases clinical studies are being conducted.


Impact of smoking and its cessation on systemic and airway immune activation
08/15/2016 - 06/30/2018 (Co-PI)
PI: Avrum Spira, MD
Boston Medical Center Corporation NIH NIDA
5R01DA042685-02


Providence/Boston Center for AIDS Research(CFAR): Core E-Biobehavioral Sciences
07/01/2018 - 06/30/2023 (PI)
Miriam Hospital NIH-NIAID

Persistent HIV expression induced type 1 IFN responses and inflammaging
08/01/2018 - 04/30/2023 (PI)
Trustees of Boston University NIH-NIAID

Impact of smoking and its cessation on systemic and airway immune activation
08/15/2016 - 06/30/2022 (PI)
NIH-NIDA
5R01DA042685-02

REPRIEVE A5332 Cardiac MRI (substudy): Mechanisms of Cardiac Dysfunction in HIV and the Effect of..
06/16/2017 - 03/31/2021 (PI)
Mass General Hosp NIH-NHLBI

MK-00036400001
01/10/2018 - 01/09/2021 (PI)
Merck

GS-US-380-4030: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy
06/19/2017 - 06/19/2020 (PI)
Gilead Sciences

Phase III, randomized, multi center…switching to dolutegravir plus lamivudine in HIV-1
11/10/2017 - 11/10/2019 (PI)
GlaxoSmithKline

GS-US-366-1160: a Phase 3b, Randomized, Souble-Blind Study to Evaluate Switching from a Regimen
06/17/2015 - 05/31/2019 (PI)
Gilead Sciences

GS-US-380-1878: A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of
05/18/2016 - 05/17/2019 (PI)
Gilead Sciences

Developing a Resilience Intervention for Aging, HIV-Infected Women
05/01/2017 - 04/30/2019 (PI)
Mass General Hosp NIH-NCCIH
5R34AT009170-02

Showing 10 of 20 results. Show All Results


Yr Title Project-Sub Proj Pubs
2018 The effects of opioid use on HIV-1 reservoir dynamics 1R61DA047038-01
2018 Persistent HIV expression induced type I IFN responses and inflammaging 1R01AG060890-01
2017 Impact of smoking and its cessation on systemic and airway immune activation 5R01DA042685-02
2016 Impact of smoking and its cessation on systemic and airway immune activation 1R01DA042685-01
2015 Analysis of properties of HIV-1 subtype C envelope glycoprotein 5K08AI081545-06 8
2014 Analysis of properties of HIV-1 subtype C envelope glycoprotein 5K08AI081545-04 8
2014 Analysis of properties of HIV-1 subtype C envelope glycoprotein 7K08AI081545-05 8
2013 Analysis of properties of HIV-1 subtype C envelope glycoprotein 5K08AI081545-03 8
2012 Analysis of properties of HIV-1 subtype C envelope glycoprotein 5K08AI081545-02 8
2011 Analysis of properties of HIV-1 subtype C envelope glycoprotein 1K08AI081545-01A2 8
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Asundi A, Robles Y, Starr T, Landay A, Kinslow J, Ladner J, White L, Plank RM, Melbourne K, Weisholtz D, Bennett M, Pan H, Stern E, Lin A, Kuritzkes DR, Lin NH. Immunological and Neurometabolite Changes associated with switch from Efavirenz to an Integrase Inhibitor. J Acquir Immune Defic Syndr. 2019 Apr 23. PMID: 31045650.
     
  2. Belkina AC, Starchenko A, Drake KA, Proctor EA, Pihl RMF, Olson A, Lauffenburger DA, Lin N, Snyder-Cappione JE. Multivariate Computational Analysis of Gamma Delta T Cell Inhibitory Receptor Signatures Reveals the Divergence of Healthy and ART-Suppressed HIV+ Aging. Front Immunol. 2018; 9:2783.View Related Profiles. PMID: 30568654.
     
  3. Olson A, Ragan EJ, Nakiyingi L, Lin N, Jacobson KR, Ellner JJ, Manabe YC, Sagar M. Brief Report: Pulmonary Tuberculosis Is Associated With Persistent Systemic Inflammation and Decreased HIV-1 Reservoir Markers in Coinfected Ugandans. J Acquir Immune Defic Syndr. 2018 Nov 01; 79(3):407-411.View Related Profiles. PMID: 30063648.
     
  4. Lin N, Gonzalez OA, Registre L, Becerril C, Etemad B, Lu H, Wu X, Lockman S, Essex M, Moyo S, Kuritzkes DR, Sagar M. Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants. EBioMedicine. 2016 Jun; 8:237-47.View Related Profiles. PMID: 27428434; PMCID: PMC4919596; DOI: 10.1016/j.ebiom.2016.04.040;.
     
  5. Scully E, Lockhart A, Huang L, Robles Y, Becerril C, Romero-Tejeda M, Albrecht MA, Palmer CD, Bosch RJ, Altfeld M, Kuritzkes DR, Lin NH. Elevated Levels of Microbial Translocation Markers and CCL2 Among Older HIV-1-Infected Men. J Infect Dis. 2016 Mar 01; 213(5):771-5. PMID: 26494772; DOI: 10.1093/infdis/jiv501;.
     
  6. Henrich TJ, Hu Z, Li JZ, Sciaranghella G, Busch MP, Keating SM, Gallien S, Lin NH, Giguel FF, Lavoie L, Ho VT, Armand P, Soiffer RJ, Sagar M, Lacasce AS, Kuritzkes DR. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis. 2013 Jun 1; 207(11):1694-702.View Related Profiles. PMID: 23460751; PMCID: PMC3636784; DOI: 10.1093/infdis/jit086;.
     
  7. Lin NH, Becerril C, Giguel F, Novitsky V, Moyo S, Makhema J, Essex M, Lockman S, Kuritzkes DR, Sagar M. Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C. Virology. 2012 Nov 25; 433(2):296-307.View Related Profiles. PMID: 22954962; PMCID: PMC3616623; DOI: 10.1016/j.virol.2012.08.013;.
     
  8. Wilkin TJ, Lalama CM, McKinnon J, Gandhi RT, Lin N, Landay A, Ribaudo H, Fox L, Currier JS, Mellors JW, Gulick R, Tenorio AR. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4? T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis. 2012 Aug 15; 206(4):534-42. PMID: 22740718; DOI: 10.1093/infdis/jis376;.
     
  9. Lin NH, Smeaton LM, Giguel F, Novitsky V, Moyo S, Mitchell RM, Makhema J, Essex M, Lockman S, Kuritzkes DR. Prevalence and clinical associations of CXCR4-using HIV-1 among treatment-naive subtype C-infected women in Botswana. J Acquir Immune Defic Syndr. 2011 May 01; 57(1):46-50. PMID: 21346588; DOI: 10.1097/QAI.0b013e318214fe27;.
     
  10. Henrich TJ, Li JZ, Felsenstein D, Kotton CN, Plenge RM, Pereyra F, Marty FM, Lin NH, Grazioso P, Crochiere DM, Eggers D, Kuritzkes DR, Tsibris AM. Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions. J Infect Dis. 2010 Nov 15; 202(10):1478-81. PMID: 20936980; DOI: 10.1086/657168;.
     
Showing 10 of 20 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 16 publications over 12 distinct years, with a maximum of 2 publications in 1993 and 2010 and 2012 and 2018

YearPublications
19921
19932
19951
19981
20102
20111
20122
20131
20151
20161
20182
20191
Contact for Mentoring:


650 Albany St Evans Biomed Research Ctr
Boston MA 02118
Google Map

617.414.5276
Download vCard

Lin's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
See all (120) concept(s)
_
Co-Authors
See all (8) people
_
Similar People
See all (60) people
_
Same Department
Search Department